Regulatory Environment - All revenues are generated in the PRC, with operations conducted through Beijing Feitian, making the company highly sensitive to political, economic, and social conditions in China [23]. - The Chinese economy has experienced uneven growth, with a slowdown since 2021, which could affect discretionary spending and orders for Beijing Feitian's products [26]. - Beijing Feitian has received all requisite licenses and approvals from PRC authorities, including a Class III Medical Device Operation License, which is valid for five years [31]. - The company plans to renew its medical device licenses and business licenses in a timely manner before expiration [31]. - Any adverse changes in Chinese government policies or economic conditions could materially affect Beijing Feitian's operations and competitive position [26]. - The PRC government's oversight could result in material adverse changes in operations and the value of securities if additional permissions are required [36]. - Regulatory changes may increase competition or lower market entry barriers, potentially affecting Beijing Feitian's market position [40]. - The company does not currently manage foreign currency exposure through hedging transactions, which could impact financial results if international revenues increase [28]. - Uncertainties in the interpretation and enforcement of PRC laws may limit legal protections and affect business operations [33]. - Beijing Feitian is not subject to cybersecurity review as it does not possess personal data of over one million users and does not anticipate reaching that threshold in the foreseeable future [41]. - The company is not currently involved in any cybersecurity investigations, but future regulatory changes could subject it to enhanced scrutiny and potential penalties [79]. - The PRC Foreign Investment Law, effective January 1, 2020, replaced previous laws regulating foreign investment, introducing uncertainties regarding its interpretation and implementation [81]. - Foreign investments must comply with a "negative list" issued by the State Council, which may impact Beijing Feitian's operations if its market falls under restricted or prohibited categories [82]. - The Chinese government exerts significant control over business operations, which may lead to increased compliance costs and potential adverse effects on the value of Class A Ordinary Shares [84]. - Compliance with PRC advertising laws is crucial, and any non-compliance could result in government sanctions, affecting the company's financial condition [87]. Financial and Tax Considerations - The company believes it is not a PRC resident enterprise for tax purposes, but if deemed so, it would face a 25% enterprise income tax on worldwide income [54]. - Dividends paid to non-resident enterprises would incur a 10% withholding tax, and gains from the sale of Class A Ordinary Shares may also be taxed at 10% [55]. - If classified as a PRC resident enterprise, dividends to non-PRC individual shareholders could be taxed at 20% [56]. - The ability of Beijing Feitian to distribute dividends is contingent on its accumulated profits as per PRC accounting standards [58]. - PRC regulations may limit the company's ability to inject capital into its operating entity or distribute profits, potentially affecting business operations [59]. - Future loans or capital contributions to Beijing Feitian require approval and registration with governmental authorities, which may delay funding [62]. - The company may face challenges in complying with evolving foreign exchange regulations, impacting its financial condition and operations [61]. - The company may not be able to complete necessary registrations or obtain approvals for future financing activities, affecting liquidity [67]. - The company faces uncertainties regarding indirect transfers of equity interests in PRC resident enterprises by offshore subsidiaries, which may lead to tax obligations under SAT Bulletin 7 and SAT Bulletin 37 [68]. - Gains from indirect transfers may be subject to a 10% PRC enterprise income tax, with both transferor and transferee potentially facing penalties for non-compliance [70]. Market and Competitive Landscape - The company relies primarily on the commercialization of FTTPS to generate revenue, expecting a majority of future revenue from FTTPS sales [106]. - The TPS market for brachytherapy has 6 approved products in China, including 3 specifically for radioactive particle implantation, indicating significant competition [119]. - The company’s growth may be impacted by decreasing customer demand, increasing competition, and changes in government policies [105]. - The company’s ability to achieve market acceptance for FTTPS depends on the strength of its sales, marketing, and distribution organizations [111]. - The company’s success is contingent on the widespread adoption of radiotherapy and brachytherapy as cancer treatments [110]. - The company may face challenges in maintaining product quality and safety, which are critical to its success [115]. - Beijing Feitian's operations are significantly impacted by U.S.-China trade relations, with the U.S. announcing 100% tariffs on all Chinese imports effective November 1, 2025, which could disrupt supply chains and increase costs [130]. - The company faces potential legal liabilities related to medical device safety, which could adversely affect its financial condition and operational results [123]. Operational Risks - The company has not identified any material quality deficiencies in its operations or those of its suppliers as of the report date [117]. - The company has limited control over third-party suppliers, and any significant interruption in their operations could adversely affect Beijing Feitian's business operations and customer relationships [127]. - The payment structure used in customer arrangements may lead to fluctuations in operating cash flows, impacting the company's financial performance if customers do not adhere to payment terms [143]. - Beijing Feitian's ability to attract and retain customers is crucial for revenue growth, with a risk of losing existing customers if competitors offer better products or services [139]. - The company does not carry business liability insurance, exposing it to significant costs and business disruptions related to potential claims and lawsuits [125]. - The company is vulnerable to intellectual property infringement claims, which could disrupt operations and adversely affect financial results [148]. - The company plans to expand operations with new products and markets, increasing the risk of intellectual property litigation [149]. - As of the date of the report, Beijing Feitian has no valid patents for its 3D printing technology, which may lead to competitive disadvantages [152]. - The company has identified three material weaknesses in its internal control over financial reporting as of December 31, 2025, which could result in inaccuracies in financial statements [159]. - The lack of business liability or disruption insurance exposes the company to significant costs and operational risks [154]. Shareholder and Governance Issues - Mr. Jianfei Zhang controls approximately 94.24% of the combined voting power of the company's equity interests through Class B Ordinary Shares [169]. - The company is considered a "controlled company" under Nasdaq standards, exempting it from certain corporate governance requirements [170]. - The dual class share structure allows Class B Ordinary Shares to have 20 votes per share compared to 1 vote for Class A Ordinary Shares, potentially limiting influence on corporate matters for Class A shareholders [183]. - The company may experience extreme share price volatility due to its small public float, making it difficult for investors to assess the value of Class A Ordinary Shares [172]. - There is a risk of delisting from the Nasdaq Capital Market if the company fails to meet listing requirements, which could negatively impact the price of its securities [186]. - Shareholders may face difficulties in protecting their interests due to the company's incorporation under Cayman Islands law, which has less developed securities laws compared to the U.S. [176]. - The company may not have a majority of independent directors due to its status as a controlled company, potentially affecting shareholder protections [170]. - The trading price of Class A Ordinary Shares may fluctuate significantly, with low trading volumes leading to greater price volatility [173]. - The company may rely on exemptions from certain Nasdaq requirements in the future, which could affect corporate governance practices [178]. - The trading volumes of Class A Ordinary Shares are low, leading to significant price fluctuations and potential losses for investors [191]. - Substantial sales or perceived sales of Class A Ordinary Shares could adversely affect their market price and impair future capital raising efforts [192]. - The company does not currently intend to pay dividends on Class A Ordinary Shares for the foreseeable future, focusing instead on operations and expansion [198]. - The company is classified as an "emerging growth company," allowing it to take advantage of reduced reporting requirements and exemptions from certain regulations [206]. - The company expects increased legal and financial compliance costs after ceasing to qualify as an "emerging growth company" due to the requirements of the Sarbanes-Oxley Act [211]. - If the company is classified as a passive foreign investment company (PFIC), U.S. taxpayers holding Class A Ordinary Shares may face adverse tax consequences [199]. - The market price of Class A Ordinary Shares may be negatively impacted if securities or industry analysts do not publish favorable research or coverage [194]. - The company may face challenges related to short selling, which could drive down the market price of Class A Ordinary Shares [195]. - The board of directors has the authority to issue additional classes or series of preferred shares, which could adversely affect the rights of Class A Ordinary Shareholders [205]. Corporate Actions and Future Plans - The company engaged Frost & Sullivan Limited for an industry report on the PRC medical device industry, with projections that may not materialize [213]. - The company sold 100,000,000 Class A ordinary shares at a purchase price of $0.2 per share, representing a discount of approximately 51.7% compared to the market price of $0.4141 on March 25, 2026 [215]. - The issuance of shares in the March 2026 Private Placement will result in substantial dilution to existing shareholders and decrease earnings per share in future periods [217]. - The company underwent a series of corporate restructuring, including the incorporation of Pheton as a holding company on November 2, 2022, and the acquisition of Beijing Feitian on March 27, 2023 [218]. - The company acquired 51% of iTonic Corporation and 30% of Geri-Safe, Ltd., issuing a total of 7,000,000 Class A ordinary shares as part of these transactions [218]. - The company is currently not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share and has until April 20, 2026, to regain compliance [218]. - The Class A ordinary shares from the private placement are subject to a six-month lock-up period, which may lead to significant selling pressure once it expires [216]. - The company has a share reserve of 2,800,000 ordinary shares under its 2025 Equity Incentive Plan approved by the board of directors [218]. - The company has authorized share consolidations at a cumulative ratio of not more than 1:4,000 within a two-year period [218]. - The acquisition of iTonic Corporation included the issuance of warrants for up to 3,000,000 Class A ordinary shares, contingent on certain milestones [218]. - The company aims to establish a new standard of care in malignant tumor applications through its healthcare solutions [218].
Pheton Holdings Ltd(PTHL) - 2025 Q4 - Annual Report